Back to Search Start Over

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Authors :
Fe. Davies
Jesús F. San-Miguel
Antonio Palumbo
H. Einsele
Ma Dimopoulos
Pieter Sonneveld
F. Leal da Costa
Roman Hájek
Meral Beksac
Gareth J. Morgan
U. H. Mellqvist
Heinz Ludwig
Michel Delforge
Sonja Zweegman
M. Attal
J L Harousseau
Radiology & Nuclear Medicine
Hematology
CCA - Innovative therapy
Source :
Leukemia, 25(5), 749-760. Nature Publishing Group, Digital.CSIC. Repositorio Institucional del CSIC, instname, Dimopoulos, M A, Palumbo, A, Attal, M, Beksac, M, Davies, F E, Delforge, M, Einsele, H, Hajek, R, Harousseau, J L, Da Costa, F L, Ludwig, H, Mellqvist, U H, Morgan, G J, San-Miguel, J F, Zweegman, S & Sonneveld, P 2011, ' Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement ', Leukemia, vol. 25, no. 5, pp. 749-760 . https://doi.org/10.1038/leu.2011.3
Publication Year :
2011

Abstract

An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. © 2011 Macmillan Publishers Limited All rights reserved.

Details

ISSN :
08876924
Volume :
25
Issue :
5
Database :
OpenAIRE
Journal :
Leukemia
Accession number :
edsair.doi.dedup.....4c7f0692125938c919a427bfc3e1ed9e
Full Text :
https://doi.org/10.1038/leu.2011.3